AdAlta Vergangene Ertragsentwicklung
Vergangenheit Kriterienprüfungen 0/6
AdAlta has been growing earnings at an average annual rate of 6.1%, while the Biotechs industry saw earnings growing at 12.6% annually. Revenues have been declining at an average rate of 7.5% per year.
Wichtige Informationen
6.1%
Wachstumsrate der Gewinne
32.1%
EPS-Wachstumsrate
Biotechs Wachstum der Industrie | 9.6% |
Wachstumsrate der Einnahmen | -7.5% |
Eigenkapitalrendite | -265.0% |
Netto-Marge | -309.7% |
Letzte Ertragsaktualisierung | 30 Jun 2024 |
Jüngste Aktualisierungen vergangener Leistungen
Recent updates
Aufschlüsselung der Einnahmen und Ausgaben
Wie AdAlta Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.
Gewinn- und Umsatzhistorie
Datum | Einnahmen | Umsatz | Allgemeine und Verwaltungskosten | F&E-Ausgaben |
---|---|---|---|---|
30 Jun 24 | 2 | -5 | 3 | 4 |
31 Mar 24 | 3 | -5 | 3 | 5 |
31 Dec 23 | 3 | -5 | 4 | 4 |
30 Sep 23 | 3 | -5 | 4 | 4 |
30 Jun 23 | 3 | -5 | 3 | 5 |
31 Mar 23 | 3 | -5 | 4 | 4 |
31 Dec 22 | 3 | -5 | 5 | 3 |
30 Sep 22 | 3 | -6 | 5 | 4 |
30 Jun 22 | 3 | -6 | 4 | 4 |
31 Mar 22 | 3 | -5 | 4 | 5 |
31 Dec 21 | 4 | -5 | 3 | 5 |
30 Sep 21 | 4 | -5 | 3 | 6 |
30 Jun 21 | 4 | -6 | 3 | 6 |
31 Mar 21 | 4 | -5 | 3 | 6 |
31 Dec 20 | 4 | -5 | 2 | 6 |
30 Sep 20 | 4 | -5 | 2 | 6 |
30 Jun 20 | 4 | -6 | 2 | 7 |
31 Mar 20 | 4 | -7 | 2 | 5 |
31 Dec 19 | 4 | -8 | 2 | 2 |
30 Sep 19 | 4 | -7 | 1 | 1 |
30 Jun 19 | 4 | -6 | 1 | 0 |
31 Mar 19 | 3 | -5 | 1 | 0 |
31 Dec 18 | 2 | -4 | 1 | 0 |
30 Sep 18 | 2 | -4 | 1 | 0 |
30 Jun 18 | 2 | -4 | 1 | 0 |
31 Mar 18 | 2 | -4 | 1 | 0 |
31 Dec 17 | 2 | -4 | 1 | 1 |
30 Sep 17 | 2 | -3 | 1 | 0 |
30 Jun 17 | 2 | -3 | 1 | 0 |
31 Mar 17 | 1 | -3 | 1 | 1 |
31 Dec 16 | 1 | -3 | 1 | 1 |
30 Sep 16 | 1 | -2 | 1 | 1 |
30 Jun 16 | 1 | -1 | 0 | 0 |
30 Jun 15 | 1 | -1 | 0 | 0 |
30 Jun 14 | 1 | -1 | 0 | 0 |
Qualität der Erträge: 1AD is currently unprofitable.
Wachsende Gewinnspanne: 1AD is currently unprofitable.
Analyse von freiem Cashflow und Gewinn
Analyse des Gewinnwachstums in der Vergangenheit
Ergebnisentwicklung: 1AD is unprofitable, but has reduced losses over the past 5 years at a rate of 6.1% per year.
Beschleunigtes Wachstum: Unable to compare 1AD's earnings growth over the past year to its 5-year average as it is currently unprofitable
Erträge im Vergleich zur Industrie: 1AD is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (2.5%).
Eigenkapitalrendite
Hohe Eigenkapitalrendite: 1AD has a negative Return on Equity (-265.03%), as it is currently unprofitable.